These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. t(4;11) leukemias display addiction to MLL-AF4 but not to AF4-MLL. Kumar AR; Yao Q; Li Q; Sam TA; Kersey JH Leuk Res; 2011 Mar; 35(3):305-9. PubMed ID: 20869771 [TBL] [Abstract][Full Text] [Related]
45. The stem cell-specific long noncoding RNA HOXA10-AS in the pathogenesis of KMT2A-rearranged leukemia. Al-Kershi S; Bhayadia R; Ng M; Verboon L; Emmrich S; Gack L; Schwarzer A; Strowig T; Heckl D; Klusmann JH Blood Adv; 2019 Dec; 3(24):4252-4263. PubMed ID: 31867596 [TBL] [Abstract][Full Text] [Related]
46. An aberrantly sustained emergency granulopoiesis response accelerates postchemotherapy relapse in Wang H; Shah CA; Hu L; Huang W; Platanias LC; Eklund EA J Biol Chem; 2020 Jul; 295(28):9663-9675. PubMed ID: 32467231 [TBL] [Abstract][Full Text] [Related]
47. MicroRNA-155 is upregulated in MLL-rearranged AML but its absence does not affect leukemia development. Schneider E; Staffas A; Röhner L; Krowiorz K; Heuser M; Döhner K; Bullinger L; Döhner H; Fogelstrand L; Rouhi A; Kuchenbauer F; Palmqvist L Exp Hematol; 2016 Dec; 44(12):1166-1171. PubMed ID: 27619068 [TBL] [Abstract][Full Text] [Related]
48. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Wong P; Iwasaki M; Somervaille TC; So CW; Cleary ML Genes Dev; 2007 Nov; 21(21):2762-74. PubMed ID: 17942707 [TBL] [Abstract][Full Text] [Related]
49. HOX expression patterns identify a common signature for favorable AML. Andreeff M; Ruvolo V; Gadgil S; Zeng C; Coombes K; Chen W; Kornblau S; Barón AE; Drabkin HA Leukemia; 2008 Nov; 22(11):2041-7. PubMed ID: 18668134 [TBL] [Abstract][Full Text] [Related]
50. HOXA9 and MEIS1 gene overexpression in the diagnosis of childhood acute leukemias: Significant correlation with relapse and overall survival. Adamaki M; Lambrou GI; Athanasiadou A; Vlahopoulos S; Papavassiliou AG; Moschovi M Leuk Res; 2015 Aug; 39(8):874-82. PubMed ID: 26059450 [TBL] [Abstract][Full Text] [Related]
51. A role for MEIS1 in MLL-fusion gene leukemia. Kumar AR; Li Q; Hudson WA; Chen W; Sam T; Yao Q; Lund EA; Wu B; Kowal BJ; Kersey JH Blood; 2009 Feb; 113(8):1756-8. PubMed ID: 19109563 [TBL] [Abstract][Full Text] [Related]
52. Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia. Zhou B; Qin Y; Zhou J; Ruan J; Xiong F; Dong J; Huang X; Yu Z; Gao S J Cell Mol Med; 2021 Mar; 25(6):3124-3135. PubMed ID: 33599085 [TBL] [Abstract][Full Text] [Related]
53. Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16. Ueda K; Yoshimi A; Kagoya Y; Nishikawa S; Marquez VE; Nakagawa M; Kurokawa M Cancer Sci; 2014 May; 105(5):512-9. PubMed ID: 24612037 [TBL] [Abstract][Full Text] [Related]
54. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Wei J; Wunderlich M; Fox C; Alvarez S; Cigudosa JC; Wilhelm JS; Zheng Y; Cancelas JA; Gu Y; Jansen M; Dimartino JF; Mulloy JC Cancer Cell; 2008 Jun; 13(6):483-95. PubMed ID: 18538732 [TBL] [Abstract][Full Text] [Related]
56. Flt3 does not play a critical role in murine myeloid leukemias induced by MLL fusion genes. Albouhair S; Morgado E; Lavau C PLoS One; 2013; 8(8):e72261. PubMed ID: 23977266 [TBL] [Abstract][Full Text] [Related]
58. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair. Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682 [TBL] [Abstract][Full Text] [Related]
59. Insights from clinical studies into the role of the MLL gene in infant and childhood leukemia. Chowdhury T; Brady HJ Blood Cells Mol Dis; 2008; 40(2):192-9. PubMed ID: 17905612 [TBL] [Abstract][Full Text] [Related]
60. Inactivation of PBX3 and HOXA9 by down-regulating H3K79 methylation represses NPM1-mutated leukemic cell survival. Zhang W; Zhao C; Zhao J; Zhu Y; Weng X; Chen Q; Sun H; Mi JQ; Li J; Zhu J; Chen Z; Pandolfi PP; Chen S; Yan X; Xu J Theranostics; 2018; 8(16):4359-4371. PubMed ID: 30214626 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]